News | March 29, 2022
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
This has further strengthened its manufacturing presence in the United States of America
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
He will continue to lead business in LATAM and Asia regions in this new role
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Subscribe To Our Newsletter & Stay Updated
